Ligand Pharmaceuticals Inc.

519 articles about Ligand Pharmaceuticals Inc.

• Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th

  1/9/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report 2019 fourth quarter and full year financial results on February 6, 2020.

• Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine

  12/23/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that two members of its Board of Directors, Nancy Gray and Sarah Boyce, have been named to WomenInc. magazine’s 2019 Most Influential Corporate Directors list.

• Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi

  12/2/2019

  Sanofi will pay Ligand an up-front platform access fee, development and regulatory milestone payments and potential royalties on sales of marketed products.

• Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™

  11/12/2019

  Ligand’s revenue grew 250% during the period upon which this list is based.

• Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

  11/8/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN Kidney Week 2019 in Washington, D.C.

• Ligand to Participate in the Stephens 2019 Nashville Investment Conference

  11/7/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. The fireside chat is scheduled to take place on Wednesday, November 13, 2019 at 3:30 p.m. Eastern Time.

• Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

  11/5/2019

  IMMUNOPRECISE ANTIBODIES LTD. announces that Talem Therapeutics, a wholly-owned subsidiary, has entered into a worldwide OmniAb® platform license agreement with Ligand Pharmaceuticals.

• Ligand Reports Third Quarter 2019 Financial Results

  11/5/2019

  Ligand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2019 and provided an operating forecast and program updates.

• Ligand to Report Third Quarter 2019 Results on November 5th

  10/22/2019

  Ligand Pharmaceuticals Incorporated announced plans to report third quarter 2019 financial results on November 5, 2019.

• Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors

  10/15/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a privately held biotechnology company pioneering the use of antibody-oligonucleotide conjugates (AOC™) to treat rare muscle disorders and other serious diseases.

• Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference

  8/29/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York City. Presentation takes place on Tuesday, September 10, 2019 at 8:45 a.m. Eastern Time.

• Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China

  8/12/2019

  It is the only approved melphalan product available in China.

• Ligand Reports Second Quarter 2019 Financial Results

  7/30/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2019, and provided an operating forecast and program updates.

• Ligand to Report Second Quarter 2019 Results on July 30th

  7/15/2019

  Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call.

• Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

  7/10/2019

  Study achieved primary endpoint demonstrating pharmacokinetic bioequivalence between Captisol-enabled Iohexol and OMNIPAQUE™

• Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation - July 8, 2019

  7/8/2019

  Ligand Pharmaceuticals Incorporated and SQ Innovation AG announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of Ligand’s Captisol® technology in the formulation of high-concentration furosemide for the treatment of edema in patients with heart failure.

• Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

  7/8/2019

  Ligand Pharmaceuticals Incorporated and SQ Innovation AG announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of Ligand's Captisol® technology in the formulation of high-concentration furosemide for the treatment of edema in patients with heart failure.

• ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics

  7/1/2019

  ZULRESSO is the 11th FDA-approved drug to use Ligand’s patented Captisol technology.

• Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target

  6/12/2019

  Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.

• Ligand Licenses VER250840 to Cumulus Oncology

  5/17/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP)